174 results about "Adipogenesis" patented technology

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Methods and compositions for treating obesity and related disorders. The methods include the use of Sca-1+ progenitor cells treated with BMP-2, -4, -5, -6, and/or -7.

The present invention discloses osteogenic and anti-adipogenic oxysterols. Agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation are disclosed. Exemplary agents include oxysterols alone or in synergistic combinations, as well as hedgehog or Wnt signaling activators. The synergistic effects of oxysterols and bone morphogenic proteins are also disclosed.

The present invention relates to methods for prevention and/or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

The present invention provides compounds, compositions, and methods for identification of motifs within regulatory regions of genes involved in adipogenesis and adipocyte differentiation. Compounds and compositions are provided for modulating expression of nuclear receptor/transcription factor-regulated genes. Methods for modulating the function of PPAR-γ as well as PPAR-γ-regulated gene promoters, and methods of using oligomeric compounds for diagnosis and treatment of diseases such as obesity and diabetes are also provided.

A wearable apparatus for the treatment or prevention of osteopenia or osteoporosis, stimulating bone growth, preserving or improving bone mineral density, and inhibiting adipogenesis is disclosed where the apparatus may generally comprise one or more vibrating elements configured for imparting repeated mechanical loads to the hip, femur, and/or spine of an individual at a frequency and acceleration sufficient for therapeutic effect. These vibrating elements may be secured to the upper body of an individual via one or more respective securing mechanisms, where the securing mechanisms are configured to position the one or more vibrating elements in a direction lateral to the individual, and the position, tension, and efficacy of these vibrating elements may be monitored and/or regulated by one or more accelerometers.

Provided herein are stem cells and methods for producing a culture of stem cells from urine. The stem cells may be differentiated into an osteogenic, chondrogenic, adipogenic, endothelial, neurogenic or myogenic lineage. Methods of use of the cells are provided, including methods of treating a subject in need of a cell based therapy.

The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating non-alcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal. The invention also provides a kit comprising a container holding a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them; and instructions for administration. The diketopiperazines have the formula given in the application.

Cellfree adipose tissue extracts, implants including the same and methods for the preparation thereof. The extracts and implants are capable of inducing adipogenesis and angiogenesis and are, thus, useful in applications including soft tissue repair and engineering and angiogenesis induction, e.g., in wound healing, treatment of burn injuries and ischemic conditions.

The invention discloses a human mesenchymal stem cell adipogenesis inducing and differentiating culture medium and a preparation method thereof. The human mesenchymal stem cell adipogenesis inducing and differentiating culture medium is produced by the following components of an alpha-MEM/HG-DMEM culture medium, 5-50% of percent by volume of fetal calf serum, 0.5-10% of percent by volume of glutamine, 100-400 [mu]M volume of indomethacin, insulin with the concentration of 0.1-20 [mu]g/ml, 10-200 [mu]M volume of 1-methyl-3-isobutyl xanthine, 10-200 nM volume of dexamethasone and 0.1-20 [mu]M volume of spermine. The preparation method includes the following steps that a culture dish is cleaned; the culture medium is provided, and the alpha-MEM/HG-DMEM culture medium is prepared in the culture dish according to a formula; materials are mixed; and mixed liquor is filtered. Multiple histologic origin human mesenchymal stem cells including human mesenchymal stem cells, umbilical cord mesenchymal stem cells and adipose tissue-derived stromal cells are induced to the directional differentiation of adipogenesis cells; differentiating and inducing time of the human mesenchymal stem cells isshortened, the preparation method is convenient, and the differentiating and the inducing of human mesenchymal stem cell adipogenesis can be achieved stably and efficiently.

The invention provides a nutrient composition capable of controlling high blood sugar of crowds suffering from type 2 diabetes and improving immunity. The nutrient composition is prepared from the following raw materials in parts by weight: 1-20 parts of a navy bean extract, 10-15 parts of inulin, 5-10 parts of resistant dextrin, 0.5-1 part of xylooligosaccharide, 0.2-0.5 part of ginseng, 0.2-0.5part of resveratrol, 2-60 parts of rhizoma polygonati, 0.5-1 part of kudzuvine roots, 0.05-0.8 part of bovine coloctrum, 0.2-0.4 part of beer yeast, 1-1.2 parts of wheat oligopeptide, 0.06-0.09 part of bitter gourd polypeptide, 0.01-0.03 part of lutein esters, 0.01-0.02 part of taurine, 0.01-0.014 part of vitamin B1, 0.01-0.014 part of vitamin B2, 0.01-0.014 part of vitamin B6, 0.00012-0.00024 part of vitamin B12 and 4-8 parts of Isomalt. The nutrient composition provided by the invention is scientifically prepared for the crowds suffering from type 2 diabetes, can solve the problem of maintaining nutrients comprehensive and balanced, can quickly and effectively control a forming mechanism for converting starch foods into sugar and a forming mechanism for converting starch foods into fat,and has the efficacy of quickly regulating blood sugar, controlling body weight, improving immunity of organisms, resisting weariness, regulating blood fat, improving osteoporosis, invigorating the kidney, tonifying the kidney and the like.

Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.

The invention discloses an identification and preparation method and application CD106-positive mesenchymal stem cells. The method comprises the following steps: identifying and isolating CD106-positive cells from mononuclear cells isolated from bone marrow, placenta or other tissues through an immunological method, carrying out adherent culture, and collecting adherent CD106-positive cells; or carrying out adherent culture of mononuclear cells isolated from bone marrow, placenta or other tissues, collecting adherent mesenchymal cells, and isolating the CD106-positive mesenchymal stem cells when the count of the obtained cells is large enough. The CD106-positive cells are mesenchymal stem cells with adherent growth, express mesenchymal stem cell-related immunological phenotype, and have osteogenesis, adipogenesis and other differentiation potencies. Compared with CD106-negative mesenchymal stem cells, the CD106-positive cells have higher immunosuppression capacity, can better inhibit proliferation of IFN-gamma (interferon-gamma) secretion of lymphocytes, and can be used for treating graft versus host disease (GVHD) and autoimmune diseases.

The invention provides a method for separating umbilical cord mesenchymal stem cell simply and effectively, which comprises the steps of separating umbilical cord mesenchymal stem cell with cannulas, digesting umbilical cord mesenchymal stem cell with trypLETM and cultivating umbilical cord mesenchymal stem cell with a serum-free medium. According to the method, an umbilical cord mesenchymal stem cell from a mother's body completely can be obtained relatively fast, and damage on the cell is relatively low; tests show that according to the method, mesenchymal stem cell can be protected to the most extent, the motility rate as well as the activity is relatively high, and adipogenesis and osteogenic induced differentiation can be carried out effectively.

The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and/or long term regulation of energy balance, short-, medium-, and/or long term regulation (stimulation and/or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and/or obesity, body weight gain and/or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Provided is a device comprising at least two layers, said at least two layers being at least partially overlapping (e.g., superposed) and contacting one another, wherein a first layer of said at least two layers comprises a non-biodegradable mesh, and wherein a second layer of the at least two layers comprises an electrospun element, and wherein the device is devoid of an extracellular matrix generated by mesenchymal progenitor cells, which are characterized by a reduced differentiation potential into an adipogenic lineage by at least about 50% as compared to differentiation potential of mesenchymal stem cells from an adult adipose source under identical assay conditions, and by an increased osteogenic differentiation potential by at least about 20% as compared to the osteogenic differentiation potential of adipose-derived MSCs under identical assays conditions.

The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-α), Interleukin-6 (IL-6) and Interleukin-1 (IL-1β).

The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

The invention discloses an induction medium inducing transdifferentiation of fibroblast into adipocyte, an induction method and application thereof. The induction medium contains a basal culture medium and an induction micromolecule combination, wherein the induction micromolecule combination is SG or 6TF, S is SB431542, G is GSK126, 6 is E61541, T is tranylcypromine, and F is forskolin. The induction medium can induce and trans-differentiate the fibrolast into the adipocyte, the obtained adipocyte contains a normal adipocyte specificity molecular tag and has a normal fat adipogenesis function, and a new approach is provided for solving the cellular source problem of regenerative medicine.